{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T04:14:49Z","timestamp":1768450489494,"version":"3.49.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100008648","name":"Pfizer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008648","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10637-025-01580-1","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T05:31:56Z","timestamp":1756963916000},"page":"924-932","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A phase 1b\/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genes"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0720-0390","authenticated-orcid":false,"given":"Karen A.","family":"Autio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos E.","family":"Kyriakopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Palyca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamid","family":"Emamekhoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Danila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehrin","family":"Jan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Catharine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elyn","family":"Riedel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Devitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Douglas","family":"Laird","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard I.","family":"Scher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"issue":"22","key":"1580_CR1","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J et al (2020) Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med 382(22):2091\u20132102","journal-title":"N Engl J Med"},{"issue":"24","key":"1580_CR2","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","volume":"383","author":"M Hussain","year":"2020","unstructured":"Hussain M et al (2020) Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med 383(24):2345\u20132357","journal-title":"N Engl J Med"},{"issue":"8","key":"1580_CR3","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJMoa2214676","volume":"388","author":"K Fizazi","year":"2023","unstructured":"Fizazi K et al (2023) Rucaparib or physician\u2019s choice in metastatic prostate cancer. N Engl J Med 388(8):719\u2013732","journal-title":"N Engl J Med"},{"issue":"10398","key":"1580_CR4","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","volume":"402","author":"N Agarwal","year":"2023","unstructured":"Agarwal N et al (2023) Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet 402(10398):291\u2013303","journal-title":"Lancet"},{"issue":"1","key":"1580_CR5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41591-023-02704-x","volume":"30","author":"K Fizazi","year":"2024","unstructured":"Fizazi K et al (2024) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nat Med 30(1):257\u2013264","journal-title":"Nat Med"},{"issue":"22","key":"1580_CR6","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.2217\/fon-2021-0153","volume":"17","author":"N Shore","year":"2021","unstructured":"Shore N et al (2021) Real-world genetic testing patterns in metastatic castration-resistant prostate cancer. Future Oncol 17(22):2907\u20132921","journal-title":"Future Oncol"},{"key":"1580_CR7","unstructured":"Shore N et al (2024) Implementation of universal germline genetic testing into standard of care for patients with prostate cancer: the time is now. JCO Oncol Pract OP2400626"},{"issue":"6","key":"1580_CR8","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1177\/10915818221121325","volume":"41","author":"M Guha","year":"2022","unstructured":"Guha M et al (2022) Comparative analyses of poly(ADP-Ribose) polymerase inhibitors. Int J Toxicol 41(6):442\u2013454","journal-title":"Int J Toxicol"},{"issue":"11","key":"1580_CR9","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1158\/1541-7786.MCR-15-0191-T","volume":"13","author":"TA Hopkins","year":"2015","unstructured":"Hopkins TA et al (2015) Mechanistic dissection of PARP1 trapping and the impact on in vivo tolerability and efficacy of PARP inhibitors. Mol Cancer Res 13(11):1465\u20131477","journal-title":"Mol Cancer Res"},{"issue":"2","key":"1580_CR10","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1158\/1535-7163.MCT-13-0803","volume":"13","author":"J Murai","year":"2014","unstructured":"Murai J et al (2014) Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther 13(2):433\u2013443","journal-title":"Mol Cancer Ther"},{"key":"1580_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.cct.2017.04.006","volume":"58","author":"W Guo","year":"2017","unstructured":"Guo W et al (2017) A Bayesian interval dose-finding design addressingOckham\u2019s razor: mTPI-2. Contemp Clin Trials 58:23\u201333","journal-title":"Contemp Clin Trials"},{"issue":"12","key":"1580_CR12","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI et al (2016) Trial design and objectives for castration-resistant prostate cancer: Updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol 34(12):1402\u20131418","journal-title":"J Clin Oncol"},{"issue":"3","key":"1580_CR13","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00428-020-02840-6","volume":"478","author":"T Takashima","year":"2021","unstructured":"Takashima T et al (2021) Immunohistochemical analysis of SLFN11 expression uncovers potential non-responders to DNA-damaging agents overlooked by tissue RNA-seq. Virchows Arch 478(3):569\u2013579","journal-title":"Virchows Arch"},{"issue":"10","key":"1580_CR14","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1158\/2159-8290.CD-19-0582","volume":"9","author":"AF Farago","year":"2019","unstructured":"Farago AF et al (2019) Combination olaparib and temozolomide in relapsed small-cell lung cancer. Cancer Discov 9(10):1372\u20131387","journal-title":"Cancer Discov"},{"issue":"12","key":"1580_CR15","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1093\/neuonc\/noaa104","volume":"22","author":"C Hanna","year":"2020","unstructured":"Hanna C et al (2020) Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial. Neuro Oncol 22(12):1840\u20131850","journal-title":"Neuro Oncol"},{"issue":"5","key":"1580_CR16","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1007\/s10637-014-0099-0","volume":"32","author":"M Hussain","year":"2014","unstructured":"Hussain M et al (2014) Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer. Invest New Drugs 32(5):904\u2013912","journal-title":"Invest New Drugs"},{"issue":"23","key":"1580_CR17","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1200\/JCO.2018.77.7672","volume":"36","author":"MC Pietanza","year":"2018","unstructured":"Pietanza MC et al (2018) Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer. J Clin Oncol 36(23):2386\u20132394","journal-title":"J Clin Oncol"},{"issue":"4","key":"1580_CR18","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1172\/JCI132031","volume":"130","author":"J Mateo","year":"2020","unstructured":"Mateo J et al (2020) Genomics of lethal prostate cancer at diagnosis and castration resistance. J Clin Invest 130(4):1743\u20131751","journal-title":"J Clin Invest"},{"issue":"5","key":"1580_CR19","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/s41416-020-01202-y","volume":"124","author":"N Coleman","year":"2021","unstructured":"Coleman N, Zhang B, Byers LA, Yap TA (2021) The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response. Br J Cancer 124(5):857\u2013859","journal-title":"Br J Cancer"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01580-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-025-01580-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01580-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:03:16Z","timestamp":1760194996000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-025-01580-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1580"],"URL":"https:\/\/doi.org\/10.1007\/s10637-025-01580-1","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Financial interests: Paul Palyca, Han Xiao, Mehrin Jan, Victoria Catharine, Elyn Riedel, and Michael Devitt declare they have no financial interests.\u00a0Karen Autio has received research support (to institution) from Amgen,\u00a0Pfizer, Johnson and Johnson, Janux Therapeutics, Astra Zeneca, Parker Institute for Cancer Immunotherapy. Karen Autio reports compensated consultant for VIR Biotech and honoraria from MashUp Media. Christos Kyriakopoulos has received research support (to institution) from Sanofi-Aventis, Gilead Sciences, Incyte Corporation, ESSA Pharma, Pionyr Immunopharma, AstraZeneca, Merck, BMS, Regeneron, Madison Vaccines, and EMD Serono. Christos Kyriakopoulos owns stock from EPIC Systems and Biogen. Daniel Danila has received research support from the US Department of Defense, American Society of Clinical Oncology, Prostate Cancer Foundation, Stand Up 2 Cancer, Amgen, Janssen Research & Development, Astellas, Medivation, Agensys, Genentech, and CreaTV. A. Douglas Laird is an employee of Pfizer and may hold Pfizer stock\/stock options. Howard Scher reports compensated consultant\/advisor to Bayer,  Pfizer Inc,  Novartis, Regeneron Pharmaceuticals, Sanofi (Genzyme Corporation) WCG Oncology and research funding (to his institution) from AIQ Solutions, Astrin, Biodesix, Epic Sciences, Janssen, Prostate Cancer Foundation and ThermoFisher. Non-financial interests: Christos Kyriakopoulos has served on advisory board for Sanofi-Aventis, Exelixis, EMD Serono, Pfizer, AVEO pharmaceuticals, and Janssen. Hamid Emamekhoo has served as an advisory board consultant for BMS, Eisai, and Cardinal Health within the last 24\u00a0months. Daniel Danila has served as a consultant for Janssen Research & Development, AstraZeneca, BioView LTD, Clovis, Astellas, Medivation, Sanador, Angle LLT, Pfizer, Agensys, Merck, and Amgen. Howard Scher reports uncompensated consultant\/advisory to AIQ Global Inc. Amgen and Janssen Research & Development, LLC, Janssen Biotech, Inc, Promontory Therapeutics; Honorarium Arsenal Capital, Physician Education Resource and non-financial support from Amgen, Astrin Biosciences, Bayer, Biodesix, Epic Sciences, Promontory Therapeutics, Pfizer Inc, Prostate Cancer Foundation, and WCG Oncology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}